BR112012012815A8 - composto derivado de 1,3-difenil-prop-2-en-1-ona, uso do referido composto, e composto, e, composição farmacêutica - Google Patents

composto derivado de 1,3-difenil-prop-2-en-1-ona, uso do referido composto, e composto, e, composição farmacêutica Download PDF

Info

Publication number
BR112012012815A8
BR112012012815A8 BR112012012815A BR112012012815A BR112012012815A8 BR 112012012815 A8 BR112012012815 A8 BR 112012012815A8 BR 112012012815 A BR112012012815 A BR 112012012815A BR 112012012815 A BR112012012815 A BR 112012012815A BR 112012012815 A8 BR112012012815 A8 BR 112012012815A8
Authority
BR
Brazil
Prior art keywords
compound
prop
diphenyl
derivatives
liver
Prior art date
Application number
BR112012012815A
Other languages
English (en)
Other versions
BR112012012815B8 (pt
BR112012012815A2 (pt
BR112012012815B1 (pt
Inventor
Hum Dean
Dufour Ingrid
Darteil Raphaël
Hanf Rémy
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of BR112012012815A2 publication Critical patent/BR112012012815A2/pt
Publication of BR112012012815A8 publication Critical patent/BR112012012815A8/pt
Publication of BR112012012815B1 publication Critical patent/BR112012012815B1/pt
Publication of BR112012012815B8 publication Critical patent/BR112012012815B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

uso de derivados de 1,3-difenilprop-2-en-1-ona para tratar distúrbios hepáticos. a invenção se refere a derivados de 1,3-difenil-prop-2-en-1-ona e a composições farmacêuticas compreendendo trais derivados para tratamento de distúrbios hepáticos, em particular aqueles necessitando da redução do nível plasmático de marcadores bioquímicos, tais como aminotransferases. os derivados de 1,3-difenil-prop-2-en-1-ona de fórmula feral (i) têm propriedades hepatoprotetoras e podem ser usados em métodos para tratar os distúrbios hepáticos envolvendo a perturbação patológica, inflamação, degeneração,e/ou proliferação de células hepáticas, tais como fibrose hepática ou doença do fígado gorduroso.
BR112012012815A 2009-11-26 2010-11-26 uso de um composto selecionado de 1-[4-metil-tio-fenil]-3-[3,5-dimetil-4-carbóxi-dimetil-metilóxi-fenil]prop-2-en-1-ona e ácido 2-[2,6-dimetil-4-[3-[4-(metil-tio)fenil]-3-oxo-propil]fenóxi]-2-metilpropanóico BR112012012815B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09306146.3 2009-11-26
EP09306146 2009-11-26
PCT/EP2010/068346 WO2011064350A1 (en) 2009-11-26 2010-11-26 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

Publications (4)

Publication Number Publication Date
BR112012012815A2 BR112012012815A2 (pt) 2017-12-12
BR112012012815A8 true BR112012012815A8 (pt) 2018-02-27
BR112012012815B1 BR112012012815B1 (pt) 2021-02-02
BR112012012815B8 BR112012012815B8 (pt) 2021-05-25

Family

ID=43587223

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012012815A BR112012012815B8 (pt) 2009-11-26 2010-11-26 uso de um composto selecionado de 1-[4-metil-tio-fenil]-3-[3,5-dimetil-4-carbóxi-dimetil-metilóxi-fenil]prop-2-en-1-ona e ácido 2-[2,6-dimetil-4-[3-[4-(metil-tio)fenil]-3-oxo-propil]fenóxi]-2-metilpropanóico

Country Status (24)

Country Link
US (2) US8772342B2 (pt)
EP (2) EP2641596B1 (pt)
JP (4) JP5833016B2 (pt)
KR (2) KR101865677B1 (pt)
CN (2) CN104434891B (pt)
AU (1) AU2010323066B2 (pt)
BR (1) BR112012012815B8 (pt)
CA (1) CA2781451C (pt)
CY (2) CY1116548T1 (pt)
DK (2) DK2641596T3 (pt)
EA (1) EA020849B1 (pt)
ES (2) ES2681794T3 (pt)
HK (1) HK1175716A1 (pt)
HU (1) HUE039731T2 (pt)
IL (2) IL219914A (pt)
LT (1) LT2641596T (pt)
MX (1) MX2012006062A (pt)
NZ (1) NZ600439A (pt)
PL (2) PL2641596T3 (pt)
PT (2) PT2504005E (pt)
SI (2) SI2641596T1 (pt)
TR (1) TR201810393T4 (pt)
WO (1) WO2011064350A1 (pt)
ZA (1) ZA201204658B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
SI2641596T1 (sl) * 2009-11-26 2018-09-28 Genfit Uporaba 1,3-difenilprop-2-en-1-on derivatov za zdravljenje motenj jeter
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
SG191772A1 (en) 2011-01-31 2013-08-30 Cadila Healthcare Ltd Treatment for lipodystrophy
EA031718B1 (ru) * 2013-01-18 2019-02-28 Женфит Лечение фиброза и рака, связанных с тирозинкиназой
AU2013387996B2 (en) 2013-04-22 2015-12-10 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (NAFLD)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (pt) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (pt) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
CN106573058B (zh) 2014-06-13 2020-05-05 伊文蒂瓦公司 用于纤维化疾病的治疗用途的ppar化合物
DK3253382T3 (da) * 2015-02-06 2022-02-14 Intercept Pharmaceuticals Inc Farmaceutiske sammensætninger til kombinationsterapi
DK3350341T3 (da) * 2015-09-14 2021-09-27 Genfit Fremgangsmåder til diagnosticering og evaluering af non-alkoholisk steatohepatitis
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
US10442761B2 (en) 2016-02-16 2019-10-15 Concert Pharmaceuticals, Inc. Deuterated GFT-505
US20220133666A1 (en) 2016-03-31 2022-05-05 Genfit Methods of treatment of cholestatic diseases
IL311687A (en) * 2016-03-31 2024-05-01 Genfit Methods for treating gallstone disease
US11331292B2 (en) 2016-03-31 2022-05-17 Genfit Methods of treatment of cholestatic diseases
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
FR3056909B1 (fr) 2016-09-30 2019-04-19 Nashpharm Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree
BR112019011740A2 (pt) 2016-12-09 2019-10-29 Cadila Healthcare Ltd composição farmacêutica e método para o tratamento de colangite biliar primária
EP3572399A4 (en) * 2017-01-22 2020-01-22 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORM OF GFT-505 AND METHOD OF PREPARING AND USING THE SAME
CN110418641A (zh) * 2017-02-24 2019-11-05 基恩菲特公司 用于组合疗法的药物组合物
EP3612175A1 (en) * 2017-04-18 2020-02-26 Genfit Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
EP3719010B1 (en) 2017-11-30 2023-07-26 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Aromatic compound, pharmaceutical composition thereof and use thereof
TW202019870A (zh) 2018-08-03 2020-06-01 法商Ｇｅｎｆｉｔ公司 艾拉菲諾鹽
US20210380521A1 (en) * 2018-10-11 2021-12-09 Basf As Aromatic compounds and pharmaceutical uses thereof
RU2702003C1 (ru) * 2019-03-18 2019-10-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный химико-фармацевтический университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФУ Минздрава России) Антистеатозное средство
US20220362187A1 (en) * 2019-04-10 2022-11-17 Genfit Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists
CN110143890B (zh) * 2019-06-12 2020-12-22 天津科技大学 一种查尔酮衍生物和合成方法及其在制备抗非酒精性脂肪肝炎药物中的应用
CN110143902B (zh) * 2019-06-12 2021-06-04 天津科技大学 含硒查尔酮衍生物Compound 1和合成方法及在抗非酒精性脂肪肝炎药物中的应用
BR112022015807A2 (pt) 2020-02-10 2023-03-14 Genfit Polimorfos de elafibranor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04202129A (ja) 1990-11-30 1992-07-22 Terumo Corp 肝障害治療薬
KR960703901A (ko) * 1993-08-19 1996-08-31 로즈 암스트롱 치환된 2(5H)푸라논, 2(5H)티오페논 및 2(5H)피롤론 유도체, 그의 제조 방법 및 엔도텔린 길항제로서의 그의 용도(Substituted 2(5H)Furanone, 2(5H)Thiophenone and 2(5H)Pyrrolone Derivatives, Their Preparation and Their Use as Endothelin antagonists)
AU2291001A (en) 1999-12-23 2001-07-03 Emory University Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
CA2413878A1 (en) * 2000-06-20 2001-12-27 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
KR100567125B1 (ko) 2001-11-01 2006-03-31 주식회사 안지오랩 칼콘 또는 이의 유도체를 함유하는 매트릭스메탈로프로테아제 활성 억제용 약학 조성물
FR2841900B1 (fr) * 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
BRPI0506718A (pt) 2004-01-08 2007-05-02 Genfit compostos, processo de preparação dos mesmos, e, composição farmacêutica ou cosmética
JP4689331B2 (ja) 2005-04-19 2011-05-25 三菱電機株式会社 撮像装置
FR2902789A1 (fr) 2006-06-21 2007-12-28 Genfit Sa Derives de 1,3-diphenylpropane substitues, preparations et utilisations
DE102006062264A1 (de) 2006-12-22 2008-06-26 Joh. Barth & Sohn Gmbh & Co. Kg Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
SI2641596T1 (sl) 2009-11-26 2018-09-28 Genfit Uporaba 1,3-difenilprop-2-en-1-on derivatov za zdravljenje motenj jeter

Also Published As

Publication number Publication date
AU2010323066B2 (en) 2014-12-11
JP5833016B2 (ja) 2015-12-16
LT2641596T (lt) 2018-08-10
CN104434891B (zh) 2018-03-30
WO2011064350A1 (en) 2011-06-03
PT2504005E (pt) 2014-01-10
DK2504005T3 (da) 2014-01-13
BR112012012815B8 (pt) 2021-05-25
KR20180031825A (ko) 2018-03-28
ZA201204658B (en) 2013-05-29
US20140309165A1 (en) 2014-10-16
HUE039731T2 (hu) 2019-01-28
AU2010323066A1 (en) 2012-06-07
JP2018070642A (ja) 2018-05-10
EP2504005B1 (en) 2013-11-06
KR101962209B1 (ko) 2019-03-26
SI2504005T1 (sl) 2014-04-30
CA2781451A1 (en) 2011-06-03
BR112012012815A2 (pt) 2017-12-12
DK2641596T3 (en) 2018-08-06
CY1116548T1 (el) 2017-03-15
NZ600439A (en) 2014-06-27
EA201290389A8 (ru) 2014-05-30
IL219914A (en) 2015-10-29
SI2641596T1 (sl) 2018-09-28
PL2641596T3 (pl) 2018-10-31
US8772342B2 (en) 2014-07-08
US20120252725A1 (en) 2012-10-04
CN102647982B (zh) 2014-10-15
PT2641596T (pt) 2018-07-31
ES2441665T3 (es) 2014-02-05
CN104434891A (zh) 2015-03-25
EP2504005A1 (en) 2012-10-03
IL219914A0 (en) 2012-07-31
EA201290389A1 (ru) 2013-01-30
US8895619B2 (en) 2014-11-25
ES2681794T3 (es) 2018-09-17
JP2020073468A (ja) 2020-05-14
HK1175716A1 (en) 2013-07-12
EP2641596B1 (en) 2018-05-02
JP2016074670A (ja) 2016-05-12
JP6594400B2 (ja) 2019-10-23
EA020849B1 (ru) 2015-02-27
CA2781451C (en) 2019-04-16
KR20120101472A (ko) 2012-09-13
MX2012006062A (es) 2012-06-28
CY1120444T1 (el) 2019-07-10
IL241791A0 (en) 2015-11-30
KR101865677B1 (ko) 2018-07-16
BR112012012815B1 (pt) 2021-02-02
TR201810393T4 (tr) 2018-08-27
JP2013512228A (ja) 2013-04-11
PL2504005T3 (pl) 2014-03-31
CN102647982A (zh) 2012-08-22
EP2641596A1 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
BR112012012815A2 (pt) composto derivado de 1,3-difenil-prop-2-en-1-ona, uso do referido composto, e composto, e, composição farmacêutica
BR112013028430A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BRPI0718803B8 (pt) composto para inibir a progressão mitótica, composição farmacêutica e método in vitro para inibir a atividade de aurora cinase em uma célula
CR10211A (es) Compuestos de tiazol y métodos de uso
BRPI0622054B8 (pt) composto e composição farmacêutica
EP2381775A4 (en) INHIBITORS OF NECROPTOSIS OF SMALL MOLECULAR SIZE
ATE495743T1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
NO20092444L (no) Heteroarylamidderivater
ECSP088923A (es) Compuestos de triazolopirazina utiles para el tratamiento de enfermedades degenerativas e inflamatorias
NO20090434L (no) Heteroarylforbindelser anvendbare som inhibitorer av E1-aktiverende enzymer
BRPI0913580B8 (pt) compostos de pirrolopiridinas como inibidores de quinase e composição farmacêutica compreendendo os referidos compostos
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
BRPI0818533B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
NI200800253A (es) Tetrahidro-pirimidoazepinas como moduladores de trpv1
EP2321264A4 (en) DEACETYLASEINHIBITORS AND APPLICATIONS THEREOF
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
BR112012014899A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
EA201200951A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
BRPI0813499B8 (pt) compostos pirimidina carboxamidas úteis como inibidores da quinase raf, composição farmacêutica compreendendo os mesmos e método de preparação dos mesmos
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
BRPI0914305B8 (pt) compostos de piridazina carboxamida substituída como compostos inibidores da quinase, uso dos compostos e uso de uma composição compreendendo os compostos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09Y Publication of grant cancelled [chapter 9.1.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 9.1 NA RPI NO 2603 DE 24/11/2020 POR TER SIDO INDEVIDA. O PARECER EMQUESTAO POSSUI INCORRECOES POIS NO QUADRO 1 DEIXOU DE MENCIONAR A VIA RELATIVA A SEQUENCIAGENETICA.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/11/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF